<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00268671</url>
  </required_header>
  <id_info>
    <org_study_id>XRP6976G_2501</org_study_id>
    <nct_id>NCT00268671</nct_id>
  </id_info>
  <brief_title>Docetaxel in Squamous Cell Carcinoma of the Head and Neck (TAX + Cisplatin in SCCHN)</brief_title>
  <official_title>Phase I/II Trial of Weekly Docetaxel and Cisplatin for Locoregional Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Study Objectives:&#xD;
&#xD;
        -  To determine the MTD (maximal tolerated dose) and recommended dose of a weekly docetaxel&#xD;
           and cisplatin combination regimen for locoregional recurrent/metastatic Squamous Cell&#xD;
           Carcinoma of the Head and Neck (SCCHN)&#xD;
&#xD;
        -  To determine the response rate of the recommended dose&#xD;
&#xD;
        -  To determine the safety and tolerability of the recommended dose&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date>April 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AE SAE collection</measure>
    <time_frame>from the inform consent signed up to the end of the study</time_frame>
  </primary_outcome>
  <enrollment>45</enrollment>
  <condition>Head and Neck Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed (of original primary tumor) locoregional recurrent and/or&#xD;
             metastatic following prior radiotherapy and/or surgery and not amenable to further&#xD;
             curative local therapy for SCCHN&#xD;
&#xD;
          -  Measurable disease as defined by at least the longest diameter measured as 20 mm by&#xD;
             conventional CT or 10 mm by spiral CT. Physical measurements are allowed if longest&#xD;
             diameter is 20 mm by caliper measurements.&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Adequate bone marrow and hepatic function as evidenced by the following:&#xD;
&#xD;
               -  Hematology (Bone marrow):&#xD;
&#xD;
                    -  Neutrophils ≥ 1.50 x 10^9/L&#xD;
&#xD;
                    -  Platelets ≥ 100 x 10^9/L&#xD;
&#xD;
                    -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
               -  Hepatic function:&#xD;
&#xD;
                    -  AST and/or ALT: &lt; 2X ULN (Upper Limit of Normal)&#xD;
&#xD;
                    -  Bilirubin &lt; 1X ULN&#xD;
&#xD;
          -  Adequate renal function with calculated or measured glomerular filtration rate of &gt; 60&#xD;
             ml/min calculated by the Cockcroft- Gault method&#xD;
&#xD;
          -  No severe intercurrent illness or other serious illness or medical conditions&#xD;
             including but not limited to:&#xD;
&#xD;
               -  Unstable cardiac disease despite treatment, myocardial infarction within 6 months&#xD;
                  prior to study entry.&#xD;
&#xD;
               -  Active uncontrolled infection&#xD;
&#xD;
               -  Active peptic ulcer&#xD;
&#xD;
               -  Chronic obstructive pulmonary disease requiring hospitalization during the year&#xD;
                  preceding study entry&#xD;
&#xD;
          -  No prior chemotherapy for recurrent/advanced SCCHN with platinum or taxane regimen&#xD;
             (primary radiosensitizing platinum allowed).&#xD;
&#xD;
          -  No other diagnosed malignancy other than basal cell carcinoma of the skin or cervix&#xD;
             carcinoma in situ&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior therapy with taxanes either adjuvant, neoadjuvant, concurrent or in advanced&#xD;
             stage disease&#xD;
&#xD;
          -  Prior chemotherapy for locoregional recurrent/metastatic SCCHN with palliative intent&#xD;
&#xD;
          -  Contraindications from&#xD;
&#xD;
               -  the medical history (i.e. known hepatitis, HIV) and physical exam&#xD;
&#xD;
               -  laboratory tests (hematology, biochemistry)&#xD;
&#xD;
               -  12-lead electrocardiogram&#xD;
&#xD;
               -  blood pressure and pulse&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breast-feeding&#xD;
&#xD;
          -  Treatment with any investigational product in the last 4 weeks before study entry&#xD;
&#xD;
          -  Likelihood of requiring treatment during the study period with drugs not permitted by&#xD;
             the clinical study protocol&#xD;
&#xD;
          -  Presence or sequelae of gastrointestinal, liver or kidney disease, or other conditions&#xD;
             known to interfere with the absorption, distribution, metabolism, or excretion of&#xD;
             drugs&#xD;
&#xD;
          -  History of hypersensitivity to the study drug(s) or to drugs with a similar chemical&#xD;
             structure&#xD;
&#xD;
          -  Impaired hepatic function, as shown by bilirubin greater than upper limits of normal&#xD;
             and/or AST greater than 2 times upper limits of normal&#xD;
&#xD;
          -  Impaired renal function, as shown by measured or calculated creatinine clearance of &lt;&#xD;
             60 ml/min or absolute creatinine level &gt; 1.5 upper limit of normal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monique Furlan</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>December 21, 2005</study_first_submitted>
  <study_first_submitted_qc>December 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2005</study_first_posted>
  <last_update_submitted>December 4, 2009</last_update_submitted>
  <last_update_submitted_qc>December 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

